Chapter

Cost-Effectiveness Analysis Abroad

Peter J. Neumann

in Using Cost-Effectiveness Analysis to Improve Health Care

Published in print December 2004 | ISBN: 9780195171860
Published online September 2009 | e-ISBN: 9780199865345 | DOI: http://dx.doi.org/10.1093/acprof:oso/9780195171860.003.0008
Cost-Effectiveness Analysis Abroad

More Like This

Show all results sharing this subject:

  • Public Health and Epidemiology

GO

Show Summary Details

Preview

This chapter focuses on how international experience in using cost-effectiveness information explicitly to inform formulary decisions provides a remarkable contrast to that of the U.S. For a number of years, the U.K., Canada, Australia, and other countries have incorporated cost-effectiveness considerations explicitly into processes for making coverage and pricing decisions about drugs and other technologies. Unlike the U.S., where there has been little public acknowledgment of limits to health resources, a number of European countries—including Norway, Denmark, Sweden, and the Netherlands—established national commissions in the 1980s and 1990s to discuss priorities and choices, and to create an explicit framework for limit setting. While these commissions elicited controversy, they were also greeted by public discussions and broad-based support of the need for a limit-setting process.

Keywords: decision-making; cost-effectiveness; NICE; priority setting; international community

Chapter.  4697 words. 

Subjects: Public Health and Epidemiology

Full text: subscription required

How to subscribe Recommend to my Librarian

Buy this work at Oxford University Press »

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.